Novartis AG’s gene therapy Luxturna for blindness is recommended for use on England’s public health service, according to the country’s healthcare cost-effectiveness watchdog NICE.
Future of HealthcareAlgorithms, Apps, Artificial Intelligence, August 2019, Blindness, Business, Diabetes, Diabetic Macular Edema, Digital therapeutics, Health Outcomes, Healthcare, Issue Archives, Marketing & Advertising, Medical Devices, Prediabetes, Smart assistants, Smart Phones, U.S. Centers for Disease Control and Prevention, Virtual Reality
I got into Healthcare six years ago and canvassed major events to gain a consensus on what the future held.
A new study shows first-time proof that AI can detect the severity of diabetic macular edema, which is a leading cause of blindness.
Roche acquires Spark Therapeutics for $4.3 billionAcquisitions, Analysts, Blindness, Blockbusters, Business, Cancer, Cells, Choroideremia, Gene Therapy, Hemophilia A, Hemophilia B, Huntington's Disease, Immune System, Immuno-oncology, Inherited Diseases, Leber’s Congenital Amaurosis, M&A, Pompe disease, Rare Diseases, Rare Genetic Diseases, Rare Inherited Disorders, Shares, Spinal Muscular Atrophy (SMA), Steroids
Roche is buying U.S.-based gene therapy specialist Spark Therapeutics for $4.3 billion after developments in this area convinced the Swiss drugmaker to “step up”, Chief Executive Severin Schwan said.
ProQR Therapeutics N.V. announced that the company received Fast Track designation from the Food and Drug Administration for QR-421a for Usher syndrome type 2.
Google said on Thursday the company had launched an artificial intelligence program in Thailand to screen for a diabetic eye disease that causes permanent blindness.
Ionis Pharmaceuticals inked a deal worth more than $700 million with pharma giant Roche to develop an antisense drug for the treatment of complement-mediated diseases.
Johnson & Johnson Vision, a broad-based global leader in eye health, launched a worldwide campaign to #spotlightsight in honor of World Sight Day on October 11, 2018.
Spark’s blindness therapy gets European panel nodBlindness, Blood Cancers, CAR-T Therapy, Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency, FDA/Regulatory, Forecasts, Gene Therapy, Genetics, Immune Response, Mutations, Recommended For Approval, Retinal Dystrophy, Spinal Muscular Atrophy (SMA), Stocks, Vision Loss
A European Medicines Agency panel recommended approval of Spark Therapeutics’ gene therapy Luxturna for blindness, a move that also boosts Swiss drugmaker Novartis that bought the rights to one of the world’s costliest treatments outside the United States.
An interim analysis of an early-stage trial showed that ProQR Therapeutics NV’s experimental treatment for a rare form of childhood blindness improved vision.